ABX-1431
ABX-1431 is a covalent, irreversible MGLL inhibitor. ABX-1431 is currently entering clinical studies for neurological disorder as well as for other indications, such as neuromyeltis optica and multiple sclero
For research use only. We do not sell to patients.
Chemical Information
| Name | ABX-1431 |
|---|---|
| Iupac Chemical Name | 1,1,1,3,3,3-Hexafluoropropan-2-yl-4-[[2-(pyrrolidin-1-yl)-4-(trifluoromethyl)phenyl]methyl]piperazine-1-carboxylate |
| Synonyms | ABX-1431; ABX 1431; ABX1431; |
| Molecular Formula | C20H22F9N3O2 |
| Molecular Weight | 507.4 |
| Smile | O=C(N1CCN(CC2=CC=C(C(F)(F)F)C=C2N3CCCC3)CC1)OC(C(F)(F)F)C(F)(F)F |
| InChiKey | SQZJGTOZFRNWCX-UHFFFAOYSA-N |
| InChi | InChI=1S/C20H22F9N3O2/c21-18(22,23)14-4-3-13(15(11-14)31-5-1-2-6-31)12-30-7-9-32(10-8-30)17(33)34-16(19(24,25)26)20(27,28)29/h3-4,11,16H,1-2,5-10,12H2 |
| CAS Number | 1446817-84-0 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | 固体粉末 |
|---|---|
| Purity | 98% Min. |
| Storage | 短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度 |
| Solubility | 可溶于DMSO |
| Handling | |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Jiang M, van der Stelt M. Activity-Based Protein Profiling Delivers Selective
Drug Candidate ABX-1431, a Monoacylglycerol Lipase Inhibitor, To Control Lipid
Metabolism in Neurological Disorders. J Med Chem. 2018 Oct 25;61(20):9059-9061.
doi: 10.1021/acs.jmedchem.8b01405. Epub 2018 Oct 11. PubMed PMID: 30354159;
PubMed Central PMCID: PMC6204598.
2: Cisar JS, Weber OD, Clapper JR, Blankman JL, Henry CL, Simon GM, Alexander JP,
Jones TK, Ezekowitz RAB, O'Neill GP, Grice CA. Identification of ABX-1431, a
Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for
Treatment of Neurological Disorders. J Med Chem. 2018 Oct 25;61(20):9062-9084.
doi: 10.1021/acs.jmedchem.8b00951. Epub 2018 Aug 23. PubMed PMID: 30067909.
Chemical Structure
